Skip to content
No results
Innopharma
  • About us
    • About us
    • Our team
    • Certifications and awards
    • Alliances
    • Working together
  • Discovery services
  • Assays
  • Facilities and technologies
  • Our research
    • Projects
    • Scientific publications
    • Spin-offs and patents
  • Resources
  • Contact us
  • About us
    • About us
    • Our team
    • Certifications and awards
    • Alliances
    • Working together
  • Discovery services
  • Assays
  • Facilities and technologies
  • Our research
    • Projects
    • Scientific publications
    • Spin-offs and patents
  • Resources
  • Contact us
    • State Research Agency (Ministry of Science, Innovation and Universities)

    ONCOMAO

    Development of new cancer therapies based on MAO-A inhibition

    • innophawp
    • 03/06/2026
    • Agencia Estatal de Investigación (Ministerio de Ciencia, Innovación y Universidades), State Research Agency (Ministry of Science, Innovation and Universities)

    PPAR4TAAD

    Development of MBF-118 as a new therapy for the treatment of Marfan syndrome and thoracic aneurysms

    • innophawp
    • 03/06/2026
    • State Research Agency (Ministry of Science, Innovation and Universities)

    GPVI collagen receptor-inhibiting antiplatelet agents for precision antithrombotic medicine

    • innophawp
    • 03/06/2026
    • State Research Agency (Ministry of Science, Innovation and Universities)

    ES-OPENSREEN (II)

    Synergies in drug discovery in Spain

    • innophawp
    • 03/06/2026
    • State Research Agency (Ministry of Science, Innovation and Universities)

    UNLOOC

    Unlocking Data Content of Organ-On-Chips

    • innophawp
    • 03/06/2026
    • State Research Agency (Ministry of Science, Innovation and Universities)

    PREDICT

    Development of a preclinical model combined with a targeted library for the selection of candidates for agnostic proof-of-concept testing in basket trials for cognitive impairment

    • innophawp
    • 03/06/2026
    • State Research Agency (Ministry of Science, Innovation and Universities)

    Systematic testing of organ-on-a-chip platforms for preclinical drug screening

    • innophawp
    • 03/06/2026
    • Agencia Estatal de Investigación (Ministerio de Ciencia, Innovación y Universidades), State Research Agency (Ministry of Science, Innovation and Universities)

    EP4Endo

    Research and development of a new therapy for the treatment of endometriosis

    • innophawp
    • 03/06/2026
    • Agencia Estatal de Investigación (Ministerio de Ciencia, Innovación y Universidades), State Research Agency (Ministry of Science, Innovation and Universities)

    PR4UF

    Discovery and clinical development of non-steroidal progesterone receptor antagonists for the treatment of uterine fibroids

    • innophawp
    • 03/06/2026
    • State Research Agency (Ministry of Science, Innovation and Universities), Centre for Technological Development and Innovation (CDTI)

    PRECINMAS

    Development of pre-candidates with novel mechanisms of action against invasive non-typhoid Salmonella

    • innophawp
    • 03/06/2026
    1 2 3
    Next
    CIMUS
    Excelencia María de Maeztu
    Members of
    EU Openscreen

    INNOPHARMA’s Drug Screening and Pharmacogenomics Platform

    CIMUS / Avenida de Barcelona, s/n 15782 Santiago de Compostela
    881 815 459 / innopharma@usc.es

    • Legal notice
    • Privacy Policy
    • Cookies policy
    • Legal notice
    • Privacy Policy
    • Cookies policy
    Manage Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}